Everything below concerns GHRH analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
==== Supplementation ==== Treating or preventing hypokalemia, a common electrolyte imbalance observed in 20% of hospital patients requires potassium supplements. There are many causes of hypokalemia, but in a clinical setting diuretics that block reabsorption of sodium and water, are the most common drug cause. A variety of prescription and over-the counter supplements are available. Potassium chloride may be dissolved in water, but the salty/bitter taste makes liquid supplements unpalatable. Potassium is also available in tablets or capsules, which are formulated to allow potassium to leach slowly out of a matrix. The mechanism of action of potassium involves various types of transporters and channels that facilitate its movement across cell membranes. This process can lead to an increase in the pumping of hydrogen ions. This, in turn, can escalate the production of gastric acid, potentially contributing to the development of gastric ulcers. An FDA ruling in the US requires warning of this issue on any non-prescription potassium pills with more than 99 mg of potassium. Studies of dietary potassium intake show higher intakes are correlated with lower blood pressures. Studies of potassium supplements to mitigate the impact of hypertension, thereby reducing cardiovascular risk, give conflicting conclusions. Some studies report "a modest but significant impact". Others find no effects. Potassium chloride and potassium bicarbonate may be useful to control mild hypertension.
=== Parkinson's disease === Parkinson's disease is the second most common neurodegenerative disease after Alzheimer's disease. It is a hypokinetic movement basal ganglia disease caused by the loss of dopaminergic neurons in the substantia nigra of the human brain. The inhibitory outflow of the basal ganglia is thus not decreased, and so upper motor neurons, mediated by the thalamus, are not activated in a timely manner. Specific symptoms include rigidity, postural problems, slow movements, and tremors. Blocking GABA receptor input from medium spiny neurons to reticulata cells, causes inhibition of upper motor neurons similar to the inhibition that occurs in Parkinson's disease.
is referred to as the chi plot. For flat surfaces, the slope of the chi plot yields the surface area. Empirically, this plot was noticed as being a very good fit to the isotherm by Michael Polanyi and also by Jan Hendrik de Boer and Cornelis Zwikker but not pursued. This was due to criticism in the former case by Albert Einstein and in the latter case by Brunauer. This flat surface equation may be used as a "standard curve" in the normal tradition of comparison curves, with the exception that the porous sample's early portion of the plot of
Sources: en.wikipedia.org
Greenland (territory of Denmark): Prime Minister Jens-Frederik Nielsen firmly stated that it would be "not respectful" to compare the democratic institutions in Greenland to those in Venezuela, stating that the reasons for another "overnight takeover" were not the same, and called on more direct communication to be had with the United States amid the proposed US acquisition of the territory. Honduras: Outgoing President Xiomara Castro strongly condemned what she described as an act of kidnapping by the United States, calling the events "an affront to the sovereignty and independence of the peoples of Latin America and the Caribbean." President Castro declared that Honduras stands "in solidarity with the brave people of Venezuela, and with President Nicolás Maduro and his wife". Jamaica: As a member of the Bureau of the Conference of Heads of Government of the Caribbean Community, Jamaica joined a statement issued following the U.S. military action that reaffirmed the principles of international law, state sovereignty and territorial integrity, and called for peaceful dialogue through diplomatic channels. Mexico: President Claudia Sheinbaum "strongly condemns and rejects" the US military action, stating that the strikes breached the United Nations Charter. She urged the US to comply with international law and end "all acts of aggression" against the Venezuelan government and people. Nicaragua: The Nicaraguan government condemned the strikes, claiming that peace in Venezuela was "gravely hurt" and called for Maduro's release.
During blood clotting, thrombin attacks the N-terminus of the Aα and Bβ chains in fibrinogen to form individual fibrin strands plus two small polypeptides, fibrinopeptides A and B derived from these respective chains. The individual fibrin strands then polymerize and are crosslinked with other fibrin strands by blood factor XIIIa to form an extensive interconnected fibrin network that is the basis for the formation of a mature fibrin clot. In addition to forming fibrin, fibrinogen also promotes blood clotting by forming bridges between, and activating, blood platelets through binding to their GpIIb/IIIa surface membrane fibrinogen receptor. Fibrin participates in limiting blood clot formation and degrading formed blood clots by at least two important mechanisms. First, it possesses three low affinity binding sites (two in fibrin's E domain; one in its D domain) for thrombin; this binding sequesters thrombin from attacking fibrinogen. Second, fibrin's Aα chain accelerates by at least 100-fold the amount of plasmin activated by tissue plasminogen activator; plasmin breaks-down blood clots. Plasmin's attack on fibrin releases D-dimers (also termed DD dimers). The detection of these dimers in blood is used as a clinical test for fibrinolysis.
== Classification == This enzyme has a classification number of EC 1.1.1.30. The first digit means that this enzyme is an oxidoreductase which means the purpose is to catalyze oxidation and reduction reaction pathways. The following two 1s indicate the subclass and sub-sub of the enzyme. In this case, 1.1.1 means this enzyme is an oxidoreductase that acts on the CH-OH group of the donor molecule using NAD(+) or NADP(+) as the acceptor. The 4th number, or 30 in this case, is the serial number of the enzyme to define it within its sub-subclass. 3-Hydroxybutryate dehydrogenase is also known as beta-hydroxybutyric dehydrogenase and is abbreviated BHBDH. Other common synonyms are shown below. The systematic name of this enzyme class is (R)-3-hydroxybutanoate:NAD+ oxidoreductase. Other names in common use include:
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.